tbuckley/cabot-search huggingface dataset:
Evaluation of the Electronic Clinical Dementia Rating for Dementia Screening
Authors: Rachel L. Nosheny, Daniel Yen, Taylor Howell, Monica Camacho, Krista Moulder, Shilpa Gummadi, Chau Bui, Sandhya Kannan, Miriam T. Ashford, Kristen Knight, Connie Mayo, Maureen McMillan, Ronald C. Petersen, Nikki H. Stricker, Erik D. Roberson, Carol Chambless, Adam Gersteneker, Roy Martin, Richard Kennedy, Yue Zhang, Walter Kukull, Derek Flenniken, Juliet Fockler, Diana Truran, R. Scott Mackin, Michael W. Weiner, John C. Morris, Yan Li
Journal: JAMA Network Open (2023)

The Clinical Dementia Rating (CDR) is a well-validated instrument widely used to detect and stage dementia due to Alzheimer disease. The digital Electronic Clinical Dementia Rating (eCDR) can be remotely self-administered and automatically scored, with potential to facilitate efficient dementia screening and staging.To evaluate the association of the eCDR with the CDR and other in-clinic assessments for screening older adults for cognitive impairment.This multisite, cross-sectional study used baseline data from a longitudinal, observational study from 2020 to 2023, including up to 3 years of follow-up. Participants were enrolled from 3 Alzheimer Disease Research Centers and the Brain Health Registry. Participants (aged ≥55 years, with a study partner, and no acute or unstable major medical conditions) were recruited during in-clinic visits or by automated emails.Participants completed the Uniform Data Set Version 3 (UDS; including the CDR) in supervised clinical research settings, and then completed the eCDR remotely, online and unsupervised, using their own device.The primary outcomes were eCDR scores (item; categorical box and global; continuous box and global), CDR scores (item; categorical box and global), and UDS assessment scores. Associations were evaluated using linear and logistic regressions.A total of 3565 participants were contacted, and 288 were enrolled. Among 173 participants with item-level data (mean [SD] age, 70.84 [7.65] years; 76 women [43.9%]), eCDR to CDR concordance was 90% or higher for 33 items (63%) and 70% to 89% for 13 items (25%). Box (domain) level concordance ranged from 80% (memory) to 99% (personal care). The global score concordance rate was 81%. κ statistics were fair to moderate. Among 206 participants with box and global scores (mean [SD] age, 71.34 [7.68] years; 95 women [46.1%]), eCDR continuous global score was associated with CDR global (categorical) score with an area under the receiver operating characteristic curve of 0.79 (95% CI, 0.70-0.87). Correlations between eCDR and in-clinic UDS assessments were similar to those between CDR sum of box scores and the same in-clinic assessments.These findings suggest that the eCDR is valid and has potential use for screening and assessment of older adults for cognitive and functional decline related to Alzheimer disease. Instrument optimization and validation in diverse cohorts in remote settings are crucial for evaluating scalability and eCDR utility in clinical research, trials, and health care settings.
The National Cancer Institute’s Cancer Disparities Research Partnership Program: a unique funding model 20 years later
Authors: C Norman Coleman, Rosemary Wong, Daniel G Petereit, Patrick D Maguire, Dwight E Heron, Michael Steinberg, Yadvindera Bains, Bhadrasain Vikram, Patricia Angelis, Alicia A Livinski, Mack Roach, Frank S Govern
Journal: JNCI Journal of the National Cancer Institute (2023)

Abstract The burden of cancer and access to effective treatment are not experienced equally by all in the United States. For underserved populations that often access the health-care system when their cancers are in advanced disease stages, radiation oncology services are essential. In 2001, the National Cancer Institute’s (NCI’s) Radiation Research Program created and implemented the Cancer Disparities Research Partnership Program (CDRP). CDRP was a pioneering funding model whose goal was to increase participation of medically underserved populations in NCI clinical trials. CDRP’s Cooperative Agreement funding supported for awardees the planning, development, and conduct of radiation oncology clinical research in institutions not traditionally involved in NCI-sponsored research and cared for a disproportionate number of medically underserved, health-disparities populations. The awardee secured and provided support for mentorship from 1 of 2 NCI comprehensive cancer centers named in its application. Six CDRP awards were made over two 5-year funding periods ending in 2013, with the end-of-program accomplishments previously reported. With the current focus on addressing equity, diversity, and inclusion, the 6 principal investigators were surveyed, 5 of whom responded about the impact of CDRP on their institutions, communities, and personal career paths. The survey that was emailed included 10 questions on a 5-point Likert scale. It was not possible to collect patient data this long after completion of the program. This article provides a 20-year retrospective of the experiences and observations from those principal investigators that can inform those now planning, building, and implementing equity, diversity, and inclusion programs.
Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA
Authors: Nick Veltmaat, Yujie Zhong, Filipe Montes de Jesus, Geok Wee Tan, Johanna A. A. Bult, Martijn M. Terpstra, Pim G. N. J. Mutsaers, Wendy B. C. Stevens, Rogier Mous, Joost S. P. Vermaat, Martine E. D. Chamuleau, Walter Noordzij, Erik A. M. Verschuuren, Klaas Kok, Joost L. Kluiver, Arjan Diepstra, Wouter J. Plattel, Anke van den Berg, Marcel Nijland
Journal: Journal of Hematology & Oncology (2023)

Abstract Diagnosing post-transplant lymphoproliferative disorder (PTLD) is challenging and often requires invasive procedures. Analyses of cell-free DNA (cfDNA) isolated from plasma is minimally invasive and highly effective for genomic profiling of tumors. We studied the feasibility of using cfDNA to profile PTLD and explore its potential to serve as a screening tool. We included seventeen patients with monomorphic PTLD after solid organ transplantation in this multi-center observational cohort study. We used low-coverage whole genome sequencing (lcWGS) to detect copy number variations (CNVs) and targeted next-generation sequencing (NGS) to identify Epstein-Barr virus (EBV) DNA load and somatic single nucleotide variants (SNVs) in cfDNA from plasma. Seven out of seventeen (41%) patients had EBV-positive tumors, and 13/17 (76%) had stage IV disease. Nine out of seventeen (56%) patients showed CNVs in cfDNA, with more CNVs in EBV-negative cases. Recurrent gains were detected for 3q, 11q, and 18q. Recurrent losses were observed at 6q. The fraction of EBV reads in cfDNA from EBV-positive patients was 3-log higher compared to controls and EBV-negative patients. 289 SNVs were identified, with a median of 19 per sample. SNV burden correlated significantly with lactate dehydrogenase levels. Similar SNV burdens were observed in EBV-negative and EBV-positive PTLD. The most commonly mutated genes were TP53 and KMT2D (41%), followed by SPEN , TET2 (35%), and ARID1A , IGLL5 , and PIM1 (29%), indicating DNA damage response, epigenetic regulation, and B-cell signaling/NFkB pathways as drivers of PTLD. Overall, CNVs were more prevalent in EBV-negative lymphoma, while no difference was observed in the number of SNVs. Our data indicated the potential of analyzing cfDNA as a tool for PTLD screening and response monitoring.
Prevalence of Thromboembolic Events in Patients With Non–Small Cell Lung Cancer and <i>RET</i> Fusions
Authors: Mihaela Aldea, Arianna Marinello, David Guyon, Anas Gazzah, Fabrice Barlesi, David Planchard, Benjamin Besse
Journal: JAMA Oncology (2023)

This cohort study examines the incidence, risks, and characteristics of deep vein thrombosis, pulmonary embolism, arterial thrombosis, and stroke among patients with non–small cell lung cancer (NSCLC) and RET fusions.
The use of ChatGPT in medical research: do we need a reporting guideline?
Authors: Xufei Luo, Janne Estill, Yaolong Chen
Journal: International Journal of Surgery (2023)

aEvidence-based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China bWHO Collaborating Centre for Guideline Implementation and Knowledge Translation, Lanzhou 730000, China cResearch Unit of Evidence-Based Evaluation and Guidelines, Chinese Academy of Medical Sciences (2021RU017), School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China dInstitute of Health Data Science, Lanzhou University, Lanzhou 730000, China eInstitute of Global Health, University of Geneva, Geneve, Switzerland Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: No.199, Donggang west road, Chengguan District, Evidence-based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China. Phone number: (+86)18219614556. E-mail address: [email protected] (Y. Chen). This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/
Predictive metabolites for incident myocardial infarction: a two-step meta-analysis of individual patient data from six cohorts comprising 7897 individuals from the COnsortium of METabolomics Studies
Authors: Ana Nogal, Taryn Alkis, Yura Lee, Domagoj Kifer, Jie Hu, Rachel A Murphy, Zhe Huang, Rui Wang-Sattler, Gabi Kastenmüler, Birgit Linkohr, Clara Barrios, Marta Crespo, Christian Gieger, Annette Peters, Jackie Price, Kathryn M Rexrode, Bing Yu, Cristina Menni
Journal: Cardiovascular Research (2023)

Abstract Aims Myocardial infarction (MI) is a major cause of death and disability worldwide. Most metabolomics studies investigating metabolites predicting MI are limited by the participant number and/or the demographic diversity. We sought to identify biomarkers of incident MI in the COnsortium of METabolomics Studies. Methods and results We included 7897 individuals aged on average 66 years from six intercontinental cohorts with blood metabolomic profiling (n = 1428 metabolites, of which 168 were present in at least three cohorts with over 80% prevalence) and MI information (1373 cases). We performed a two-stage individual patient data meta-analysis. We first assessed the associations between circulating metabolites and incident MI for each cohort adjusting for traditional risk factors and then performed a fixed effect inverse variance meta-analysis to pull the results together. Finally, we conducted a pathway enrichment analysis to identify potential pathways linked to MI. On meta-analysis, 56 metabolites including 21 lipids and 17 amino acids were associated with incident MI after adjusting for multiple testing (false discovery rate &amp;lt; 0.05), and 10 were novel. The largest increased risk was observed for the carbohydrate mannitol/sorbitol {hazard ratio [HR] [95% confidence interval (CI)] = 1.40 [1.26–1.56], P &amp;lt; 0.001}, whereas the largest decrease in risk was found for glutamine [HR (95% CI) = 0.74 (0.67–0.82), P &amp;lt; 0.001]. Moreover, the identified metabolites were significantly enriched (corrected P &amp;lt; 0.05) in pathways previously linked with cardiovascular diseases, including aminoacyl-tRNA biosynthesis. Conclusions In the most comprehensive metabolomic study of incident MI to date, 10 novel metabolites were associated with MI. Metabolite profiles might help to identify high-risk individuals before disease onset. Further research is needed to fully understand the mechanisms of action and elaborate pathway findings.
Metastases-Targeting Radiotherapy and ADT
Authors: Jui-Ming Liu, Yung-Shuo Kao
Journal: JAMA Oncology (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Gut microbiota promotes stem cell differentiation through macrophage and mesenchymal niches in early postnatal development
Authors: Ji-Eun Kim, Bo Li, Lijiang Fei, Rachael Horne, Dorothy Lee, Adrian Kwan Ho Loe, Hiromu Miyake, Eda Ayar, Maria Gurma, Dae-Kyum Kim, Michael G. Surette, Dana J. Philpott, Philip Sherman, Guoji Guo, Agostino Pierro, Tae-Hee Kim
Journal: Immunity (2023)
NCCN CNS tumor guidelines update for 2023
Authors: Burt Nabors, Jana Portnow, Jona Hattangadi-Gluth, Craig Horbinski
Journal: Neuro-Oncology (2023)

Journal Article NCCN CNS tumor guidelines update for 2023 Get access Burt Nabors, Burt Nabors Department of Neurology, Division of Neuro-oncology; Departments of Neurology and Neurosurgery, O'Neal Comprehensive Cancer Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama Corresponding Author: Burt Nabors, MD, Department of Neurology, Division of Neuro-oncology; Departments of Neurology and Neurosurgery, O'Neal Comprehensive Cancer Center, Heersink School of Medicine, University of Alabama at Birmingham, 510 20th Street South, FOT 1020, Birmingham, AL 35294, USA (bnabors@uab.edu) https://orcid.org/0000-0001-5926-2230 Search for other works by this author on: Oxford Academic PubMed Google Scholar Jana Portnow, Jana Portnow Department of Medical Oncology and Research Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California Search for other works by this author on: Oxford Academic PubMed Google Scholar Jona Hattangadi-Gluth, Jona Hattangadi-Gluth Moores Cancer Center, University of California San Diego, San Diego, California Search for other works by this author on: Oxford Academic PubMed Google Scholar Craig Horbinski Craig Horbinski Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois https://orcid.org/0000-0001-8340-9992 Search for other works by this author on: Oxford Academic PubMed Google Scholar Neuro-Oncology, Volume 25, Issue 12, December 2023, Pages 2114–2116, https://doi.org/10.1093/neuonc/noad169 Published: 14 September 2023 Article history Published: 14 September 2023 Corrected and typeset: 25 September 2023
Re-sleeve gastrectomy is a safe and sensible intervention in selected patients: retrospective cohort study
Authors: Lionel El Khoury, Jean-Marc Catheline, Malak Taher, Joel Roussel, Yasmina Bendacha, Rodolfo Romero, Rami Dbouk, Regis Cohen
Journal: International Journal of Surgery (2023)

Introduction: Sleeve gastrectomy (SG) is a good treatment intervention to control metabolic syndrome in patients with obesity worldwide. However, weight regain is of great concern and would usually necessitate a re-intervention. In recent years, re-sleeve gastrectomy (ReSG) has been proposed to treat weight regain in the context of a large residual stomach. Our objective was to analyze the long-term results and safety profile of this intervention in a large case series. Methods: From September 2010 to March 2021, a retrospective cohort study in a tertiary non-university hospital was performed. Seventy-nine patients received a ReSG by laparoscopy. Pre-operative radiologic imaging showed a dilation of the gastric pouch exceeding 250 cc in all cases. Results: A total of seventy-nine patients (87% females) with a mean age of 44.8 years old and a mean Body Mass Index (BMI) of 40.0 kg/m 2 were enrolled in the study. The mean follow-up was 44.8 months. The ReSG indication was insufficient weight loss in 37 patients (46.8%) and weight regain in 39 patients (53.2%). We noticed a 10.1% complications rate: gastric stenosis (5.1%), bleeding (2.5%), and incisional site hernia in 2.5%, with no death. There was no gastric fistula detected. The mean BMI decreased to 33.1 kg/m 2 after ReSG (a decrease of 6.9 kg/m 2 ). Conclusion: After insufficient weight loss or weight regain following sleeve gastrectomy and in presence of localized or global gastric tube dilation, ReSG seems to be a good treatment choice and a safe procedure.
Individualized Stereotactic Ablative Radiotherapy for Lung Tumors
Authors: Michael F. Gensheimer, Harriet Gee, Hiroki Shirato, Hiroshi Taguchi, John M. Snyder, Alexander L. Chin, Lucas K. Vitzthum, Peter G. Maxim, Heather A. Wakelee, Joel Neal, Millie Das, Daniel T. Chang, Elizabeth Kidd, Steven L. Hancock, David B. Shultz, Kathleen C. Horst, Quynh-Thu Le, Samantha Wong, Eleanor Brown, Ngan Nguyen, Rachel Liang, Billy W. Loo, Maximilian Diehn
Journal: JAMA Oncology (2023)

Stereotactic ablative radiotherapy (SABR) is used for treating lung tumors but can cause toxic effects, including life-threatening damage to central structures. Retrospective data suggested that small tumors up to 10 cm3 in volume can be well controlled with a biologically effective dose less than 100 Gy.
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial
Authors: Tina Cascone, Gozde Kar, Jonathan D. Spicer, Rosario García-Campelo, Walter Weder, Davey B. Daniel, David R. Spigel, Maen Hussein, Julien Mazieres, Julio Oliveira, Edwin H. Yau, Alexander I. Spira, Valsamo Anagnostou, Raymond Mager, Oday Hamid, Lin-Yang Cheng, Ying Zheng, Jorge Blando, Tze Heng Tan, Michael Surace, Jaime Rodriguez-Canales, Vancheswaran Gopalakrishnan, Bret R. Sellman, Italia Grenga, Yee Soo-Hoo, Rakesh Kumar, Lara McGrath, Patrick M. Forde
Journal: Cancer Discovery (2023)

Abstract Neoadjuvant chemoimmunotherapy improves pathologic complete response rate and event-free survival in patients with resectable non–small cell lung cancer (NSCLC) versus chemotherapy alone. NeoCOAST was the first randomized, multidrug platform trial to examine novel neoadjuvant immuno-oncology combinations for patients with resectable NSCLC, using major pathologic response (MPR) rate as the primary endpoint. Eighty-three patients received a single cycle of treatment: 26 received durvalumab (anti–PD-L1) monotherapy, 21 received durvalumab plus oleclumab (anti-CD73), 20 received durvalumab plus monalizumab (anti-NKG2A), and 16 received durvalumab plus danvatirsen (anti-STAT3 antisense oligonucleotide). MPR rates were higher for patients in the combination arms versus durvalumab alone. Safety profiles for the combinations were similar to those of durvalumab alone. Multiplatform immune profiling suggested that improved MPR rates in the durvalumab plus oleclumab and durvalumab plus monalizumab arms were associated with enhanced effector immune infiltration of tumors, interferon responses and markers of tertiary lymphoid structure formation, and systemic functional immune cell activation. Significance: A neoadjuvant platform trial can rapidly generate clinical and translational data using candidate surrogate endpoints like MPR. In NeoCOAST, patients with resectable NSCLC had improved MPR rates after durvalumab plus oleclumab or monalizumab versus durvalumab alone and tumoral transcriptomic signatures indicative of augmented immune cell activation and function. See related commentary by Cooper and Yu, p. 2306. This article is featured in Selected Articles from This Issue, p. 2293
Personalized Radiation Therapy—Spurning the “One Size Fits All” Approach
Authors: Vivek Verma
Journal: JAMA Oncology (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Mental Health Outcomes Among Patients Living in US Counties Lacking Broadband Access and Psychiatrists
Authors: Tarun Ramesh, Ryan K. McBain, Jonathan H. Cantor, Bradley D. Stein, Hao Yu
Journal: JAMA Network Open (2023)

This cross-sectional study identifies the prevalence of counties without psychiatrists and broadband coverage, describes their sociodemographic characteristics, and quantifies their mental health outcomes.
A commentary on ‘Incidence and risk factors for postoperative pancreatic fistula in 2089 patients treated by radical gastrectomy: A prospective multicenter cohort study in China’
Authors: Chengwu Tang, Hongbin Yu, Wenming Feng
Journal: International Journal of Surgery (2023)

Department of General Surgery, First affiliated Hospital of Huzhou University, Zhejiang, China, 313000 All data in this manuscript is available and transparent for readers. Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: Department of General Surgery, First affiliated Hospital of Huzhou University, Zhejiang, China, 313000. E-mail address: [email protected] (W. Feng). This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/
Clinical results after external reinforcement of colorectal anastomosis: a systematic review
Authors: Clara Gené Škrabec, Manel Cremades Pérez, Andrea Fernández Pujol, Sara Cortinovis, Javier Corral Rubio, Joan-Francesc Julián Ibáñez, David Parés
Journal: International Journal of Surgery (2023)

The aim of this review is to describe and assess the existing methods to cover colorectal anastomoses with biomaterials and their clinical impact in reducing anastomotic leakage (AL).